MW 001

Drug Profile

MW 001

Alternative Names: MW-001

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator MedWell Laboratories
  • Class Anti-inflammatories
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Eczema; Multiple sclerosis; Non-alcoholic fatty liver disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Highest Development Phases

  • Phase I/II Atopic dermatitis; Eczema; Psoriasis
  • Preclinical Multiple sclerosis; Non-alcoholic fatty liver disease; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 05 Aug 2016 Phase-I/II clinical trials in Psoriasis in Israel (Topical)
  • 05 Aug 2016 Phase-I/II clinical trials in Eczema (In adults) in Israel (Topical)
  • 05 Aug 2016 Phase-I/II clinical trials in Atopic dermatitis (In children, In infants, In neonates, In adolescents) in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top